Rappta Therapeutics Oy has signed an exclusive global license agreement with Springworks Therapeutics Inc. for RPT-04402, a first-in-class molecular glue of specific protein phosphatase 2A (PP2A) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback